docs(iva): record G2K P008 QA candidate and preserved balance
This commit is contained in:
@@ -6819,5 +6819,163 @@
|
||||
"installed-public-delta.json": "25cf1ea0d7ad86488db226b8cf242b2f6ee79f7271650d236e4a37423c9d5a12",
|
||||
"manifest-served.json": "2f3fd204e659ac71f0e35b59365b7342d79f1460119ef34a4daa217e4b21c0af"
|
||||
}
|
||||
},
|
||||
"iva_l1_g2_pharma_inputs_qa_20261024": {
|
||||
"candidate": "8882dc54d0973bc058b04009bdbc36c9da2cc31b",
|
||||
"status": "demonstrated_QA_not_installed",
|
||||
"base_homologation": "e45a1394fa2ca8631593549b3af62093f25d9c13",
|
||||
"base_receipt": "eb9e0dbc",
|
||||
"group": "G2K within G2",
|
||||
"branches": {
|
||||
"AUD-SIM-L1-P008": [
|
||||
"pharma_manufacturing_inputs"
|
||||
]
|
||||
},
|
||||
"branch_count": 1,
|
||||
"treatment_count": 1,
|
||||
"annex_documentary_rows": 170,
|
||||
"annex_distinct_codes": 169,
|
||||
"annex_version": "annexIII-lei22-2022/1",
|
||||
"annex_transcription_sha256": "861b660fc124f2e33cbefb30bdb2a0a9680c471d5c6ecfedc883c3a5fc81bdf7",
|
||||
"sources": [
|
||||
{
|
||||
"path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\Lei-13-2016-CIVA-BR-156-10-suplemento.pdf",
|
||||
"sha256": "b90dc7c14ecea2e378c4a62e8e5a47d54a5644c457baeb8b8053b92fd2a5710b",
|
||||
"citations": [
|
||||
"9(1)(g),PDF9/p1426(267)",
|
||||
"19(1),PDF15/p1426(273)"
|
||||
]
|
||||
},
|
||||
{
|
||||
"path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\BR-89-I-Serie-2017-06-08.pdf",
|
||||
"sha256": "11f0cab15eb6e51010952203ffa24fdc533a24fd642e19525fe4f46b17a1f5e5",
|
||||
"citations": [
|
||||
"Annex rectification,PDF1/p569"
|
||||
]
|
||||
},
|
||||
{
|
||||
"path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\Lei-22-2022-IVA-republicada-BR-250-2-suplemento.pdf",
|
||||
"sha256": "ea1b0dc6f5cf6e595f6d9a19e7042f398999e0087caef1785f6e8fac571b5f53",
|
||||
"citations": [
|
||||
"art3(1),art6,PDF4/p2252(28)",
|
||||
"AnexoIII PDF12-16/p2252(36)-(40)"
|
||||
],
|
||||
"visual_pages_checked": [
|
||||
12,
|
||||
13,
|
||||
14,
|
||||
15,
|
||||
16
|
||||
]
|
||||
}
|
||||
],
|
||||
"scope": "2026/MZN/07; internal transmission by the SNS-integrated public/private establishment itself; manufacturing use; cumulative code/designation; no automatic deduction or ATsubmission",
|
||||
"new_optional_field": "pharmaAnnexItem; selected documentary row identity, not an inferred tariff code",
|
||||
"documentary_identity": {
|
||||
"duplicated_code": "2912.19.00",
|
||||
"separate_ids": [
|
||||
"annexIII-2022-084",
|
||||
"annexIII-2022-085"
|
||||
],
|
||||
"printed_position": "2935.",
|
||||
"no_missing_digits_invented": true,
|
||||
"continuation_pages_preserved": true,
|
||||
"text_layer_correction": "Anitibióticos -> printed Antibióticos; original unchanged"
|
||||
},
|
||||
"tests": {
|
||||
"new_frontend": 3,
|
||||
"API_QA_tests": 1,
|
||||
"API_QA_assertions": 27,
|
||||
"UI_revision": 4,
|
||||
"UI_search_preserves_selection": true,
|
||||
"UI_missing_annex_indeterminate": true,
|
||||
"UI_missing_transmitter_SNS_condition_indeterminate": true,
|
||||
"UI_reload_preserves_state": true,
|
||||
"UI_to_API_to_report": true,
|
||||
"report_visual_HTML": true,
|
||||
"types": "passed",
|
||||
"build": "passed",
|
||||
"accepted_Word_PDF_fraction_proofs": "reused;renderersunchanged;no new pagination claim"
|
||||
},
|
||||
"example": {
|
||||
"scope": "opportunity:320",
|
||||
"location": "Manica",
|
||||
"period": "2026-12",
|
||||
"currency": "MZN",
|
||||
"rows": 5,
|
||||
"07": "500.00",
|
||||
"05": "0.00",
|
||||
"VAT": "0.00"
|
||||
},
|
||||
"preservation": {
|
||||
"delivered_branches": 34,
|
||||
"matrix_delivered_rows_unchanged": true,
|
||||
"frozen_books_unchanged_and_current_without_recalculation": 11,
|
||||
"calendar_version": "production-option/2 unchanged",
|
||||
"manual_accepted_tests_repeated": false,
|
||||
"active_data_writes": 0,
|
||||
"schema_or_permission_changes": false
|
||||
},
|
||||
"counts": {
|
||||
"delivered": 34,
|
||||
"demonstrated_QA": 1,
|
||||
"functional_pending": 97,
|
||||
"documentary_pending": 1,
|
||||
"total": 133
|
||||
},
|
||||
"G2_counts": {
|
||||
"total": 32,
|
||||
"delivered": 30,
|
||||
"QA": 1,
|
||||
"functional_pending": [
|
||||
"P035"
|
||||
]
|
||||
},
|
||||
"conditional_treatments_total": 73,
|
||||
"indeterminate_options": 2,
|
||||
"P001_scope": "05/06 only; not resolved",
|
||||
"L1_complete": false,
|
||||
"homologation_unchanged": true,
|
||||
"statistics_AI": "deferred",
|
||||
"new_source_acquisition": {
|
||||
"path": "C:\\laragon\\www\\portal-investidor\\docs\\investmoz\\simulations\\source-archive\\BR-95-I-Suplemento-2025-05-21.pdf",
|
||||
"origin": "https://archive.gazettes.africa/archive/mz/2025/mz-government-gazette-series-i-supplement-dated-2025-05-21-no-95.pdf",
|
||||
"sha256": "e0e682e2c027c3cd9c1d46a73a3f48bc5f6bdbf05667fd97314d7a3f6a456358",
|
||||
"pages": 2,
|
||||
"citations": [
|
||||
"Lei3/2025art1,PDF1/p478(1):only9(13),term31Dec2025",
|
||||
"PDF2/p478(2):9(13)f;art2publicationdate;AnexoII"
|
||||
],
|
||||
"visual_checked": true,
|
||||
"source_inventory": "existing inventario-fontes.csv, one row appended; previous rows unchanged",
|
||||
"matrix_documentary_dependency_only": [
|
||||
"P038",
|
||||
"P039",
|
||||
"P040",
|
||||
"P041",
|
||||
"P042",
|
||||
"P043"
|
||||
],
|
||||
"G3_implemented_or_activated": false,
|
||||
"original_imported_or_published_in_active_database": false
|
||||
},
|
||||
"artifacts": {
|
||||
"frontend-tests.txt": "c8a066cff1d311939cc03257251e096920290794c7b10cd0102b99593440c4d6",
|
||||
"api-tests.xml": "a6eef076a6745b8e8e4fc3c7d8b8ad84c2b8d8f2edfdd234d20592a2b57ecfed",
|
||||
"api-ui-tests.xml": "5c495881cce29615aaf24c3861bb343588106ab01ef98c60043afb7a2512c5dc",
|
||||
"ui-calculated.json": "a094479ab5e6edeb880b69cf0b86b519dc4b78496a3013c94d0a68d8f66a5b76",
|
||||
"recovered.json": "071216959dbea3c1df196ef1679b8bc0e287cda95ee754c7b25886a7da233067",
|
||||
"pharma-model.json": "022b4ed5a60ecef92ee5a6d802f1afc6134439f43196e50e569881007e61324d",
|
||||
"pharma-report.html": "edba8b3ba91956ed38ddaf2c5c73cdd44052d9412bfcb9348e8e166b209cca26",
|
||||
"report-qa.png": "64b6634aac1a1f6a835ff96458db747d569e62267dc2800246fbe45f31d3648a",
|
||||
"types.txt": "82962651e47f564de653ad2883f8fd34e7dae4b4468e4ac459cb3331962a3879",
|
||||
"build.txt": "e80105992bba4531c0046d302cee2d71eb38a6f797af836eda33776e2365b646",
|
||||
"annexIII-extracted.json": "8cc1678e2b6580ce64ddf56e291c7ba37b8702302a135480b500c8a0b13ce59d",
|
||||
"annexIII-12.png": "8f5f68201651f2213db4d9d52916118785928d687ae794ee6dea5ce0eea27ec2",
|
||||
"annexIII-13.png": "fdc9fc486b371876572c48af39d541325449f1aa8d8e77ad2650ed8f71ca621b",
|
||||
"annexIII-14.png": "585afde16f8fac6608f0d1dbad412ffb296fb7d0bfd0f19ee6a5d226408000f9",
|
||||
"annexIII-15.png": "5400e7104604e46e61e5af9005664abaab08e5c0330909f4b10d624a3da69489",
|
||||
"annexIII-16.png": "c8af2c702e6e2f592987666bce00a09f7ec947ff8034f7c9e173f29774060c8c"
|
||||
}
|
||||
}
|
||||
}
|
||||
|
||||
@@ -2,7 +2,7 @@
|
||||
|
||||
## 24/10/2026 — G2K / P008 demonstrado em QA
|
||||
|
||||
**Um ramo, um tratamento: `pharma_manufacturing_inputs`.** Homologação permanece em `e45a1394`, recibo `eb9e0dbc`; os34 ramos entregues, incluindo G2I/G2J e calendário, continuam encerrados. L1 aberto; P001 exclusivamente05/06. Estatísticas/IA adiadas.
|
||||
**Candidata `8882dc54d0973bc058b04009bdbc36c9da2cc31b`; um ramo, um tratamento: `pharma_manufacturing_inputs`.** Homologação permanece em `e45a1394`, recibo `eb9e0dbc`; os34 ramos entregues, incluindo G2I/G2J e calendário, continuam encerrados. L1 aberto; P001 exclusivamente05/06. Estatísticas/IA adiadas.
|
||||
|
||||
### Fonte, cobertura e correspondência executável
|
||||
|
||||
|
||||
Reference in New Issue
Block a user